Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923612 | 0.89 | CA1 (0.36) | — | |
| SCHEMBL7648893 | 0.87 | TAS2R14 (0.31) | — | |
| SCHEMBL6926884 | 0.85 | GRIN2D (0.31) | — | |
| SCHEMBL7648880 | 0.85 | CNR2 (0.32) | — | |
| SCHEMBL7647679 | 0.85 | KDM4E (0.33) | — | |
| SCHEMBL6926207 | 0.84 | GRIN1 (0.38) | — | |
| SCHEMBL7648078 | 0.84 | KDM4E (0.36) | — | |
| SCHEMBL6928527 | 0.82 | PARP1 (0.40) | — | |
| SCHEMBL7199614 | 0.80 | EGLN1 (0.30) | — | |
| SCHEMBL7068983 | 0.78 | PARP1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596709-B1 | For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea | LES LABORATOIRES SERVIER (FR) | 2003-07-22 | — | — | US | disclosed |
| US-6518258-B1 | 6-sulphamoyl -3-quinolyphosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2003-02-11 | — | — | US | disclosed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| CN-1320601-A | 6-amino or 6-hydrazino-sulfonyl-3-quinolyl phosphonic acid compound, preparing process thereof and pharmaceutical composition contg. same | ADIR (FR) | 2001-11-07 | — | — | CN | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
| CN-1317490-A | Novel-6-sulfamine-3-quinolyl phosphonate compounds, its prepn. process and medical compsn. contg. them | ADIR (FR) | 2001-10-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | TRPV4 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.